| A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis A Vecchione, B Belletti, F Lovat, S Volinia, G Chiappetta, S Giglio, ... Proceedings of the National Academy of Sciences 110 (24), 9845-9850, 2013 | 169 | 2013 |
| The use of bevacizumab in non-small cell lung cancer: an update S Lauro, CE Onesti, R Righini, P Marchetti Anticancer research 34 (4), 1537-1545, 2014 | 74 | 2014 |
| The sexist behaviour of immune checkpoint inhibitors in cancer therapy? A Botticelli, CE Onesti, I Zizzari, B Cerbelli, P Sciattella, M Occhipinti, ... Oncotarget 8 (59), 99336, 2017 | 25 | 2017 |
| High-doses of proton pump inhibitors in refractory gastro-intestinal cancer: a case series and the state of art R Falcone, M Roberto, C D’Antonio, A Romiti, A Milano, CE Onesti, ... Digestive and Liver Disease 48 (12), 1503-1505, 2016 | 23 | 2016 |
| Pharmacogenomics in lung cancer chemotherapy: a review of what the oncologist should know C D'ANTONIO, A Milano, R Righini, CE Onesti, M Bassanelli, R Falcone, ... Anticancer research 34 (10), 5241-5250, 2014 | 20 | 2014 |
| Continuous, low-dose capecitabine for patients with recurrent colorectal cancer A Romiti, CE Onesti, M Roberto, V Barucca, S Tomao, C D’Antonio, ... Medical Oncology 32 (3), 54, 2015 | 19 | 2015 |
| PD-L1 expression in TNBC: a predictive biomarker of response to neoadjuvant chemotherapy? B Cerbelli, A Pernazza, A Botticelli, L Fortunato, M Monti, P Sciattella, ... BioMed research international 2017, 2017 | 16 | 2017 |
| Precision medicine for metastatic breast cancer. AF Deluche E, Onesti E Am Soc Clin Oncol Educ Book 35, e2-e7, 2015 | 14 | 2015 |
| Lean body mass wasting and toxicity in early breast cancer patients receiving anthracyclines F Mazzuca, CE Onesti, M Roberto, M Di Girolamo, A Botticelli, P Begini, ... Oncotarget 9 (39), 25714, 2018 | 13 | 2018 |
| Molecular detection of EMT markers in circulating tumor cells from metastatic non-small cell lung cancer patients: potential role in clinical practice A Milano, F Mazzetta, S Valente, D Ranieri, L Leone, A Botticelli, ... Analytical Cellular Pathology 2018, 2018 | 12 | 2018 |
| A metronomic schedule as salvage chemotherapy for upper gastrointestinal tract cancer M Roberto, A Romiti, CE Onesti, C D’Antonio, A Milano, R Falcone, ... Anti-cancer drugs 27 (2), 106-111, 2016 | 12 | 2016 |
| Prognosis of elderly gastric cancer patients after surgery: a nomogram to predict survival M Roberto, A Botticelli, L Strigari, M Ghidini, CE Onesti, M Ratti, I Benzoni, ... Medical Oncology 35 (7), 111, 2018 | 11 | 2018 |
| Recent advances for the treatment of pancreatic and biliary tract cancer after first-line treatment failure CE Onesti, A Romiti, M Roberto, R Falcone, P Marchetti Expert review of anticancer therapy 15 (10), 1183-1198, 2015 | 11 | 2015 |
| Atypical patterns of response to immune checkpoint inhibitors: interpreting pseudoprogression and hyperprogression in decision making for patients’ treatment CE Onesti, P Frères, G Jerusalem Journal of Thoracic Disease 11 (1), 35, 2019 | 9 | 2019 |
| The TYMS-TSER polymorphism is associated with toxicity of low-dose capecitabine in patients with advanced gastrointestinal cancer A Romiti, M Roberto, C D’Antonio, CE Onesti, V Barucca, A Milano, ... Anti-cancer drugs 27 (10), 1044-1049, 2016 | 9 | 2016 |
| Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine M Roberto, A Romiti, A Botticelli, F Mazzuca, L Lionetto, G Gentile, I Paris, ... European journal of clinical pharmacology 73 (2), 157-164, 2017 | 8 | 2017 |
| Degradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker? MF Botticelli A, Borro M, Onesti CE, Strigari L, Gentile G, Cerbelli B ... PLoS One 11 (9), e0163105, 2016 | 8 | 2016 |
| Hyperprogressive disease and early hypereosinophilia after anti-PD-1 treatment: a case report M Occhipinti, R Falcone, CE Onesti, P Marchetti Drug safety-case reports 5 (1), 12, 2018 | 6 | 2018 |
| A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient A Botticelli, CE Onesti, L Strigari, M Occhipinti, FR Di Pietro, B Cerbelli, ... Anti-cancer drugs 28 (5), 551-556, 2017 | 6 | 2017 |
| Pharmacogenetic approach to toxicity in breast cancer patients treated with taxanes S Angelini, A Botticelli, CE Onesti, R Giusti, V Sini, V Durante, L Strigari, ... Anticancer research 37 (5), 2633-2639, 2017 | 6 | 2017 |
Maurizio SimmacoUniversità La Sapienza - Azienda Ospedaliera Sant'Andrea - RomaVerified email at uniroma1.it
